Enhanced dissolution and stability of lansoprazole by cyclodextrin inclusion complexation: Preparation, characterization, and molecular modeling

AAPS PharmSciTech

Volumn 13, Issue 4, 2012, Pages 1222-1229

  Lu, Yi ^a   Guo, Tao ^b   Qi, Jianping ^a   Zhang, Jiwen ^b,c   Wu, Wei ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

cyclodextrin; dissolution; inclusion complex; lansoprazole; molecular modeling; stability

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; LANSOPRAZOLE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ILLUMINATION; INFRARED SPECTROSCOPY; MOLECULAR MODEL; PRIORITY JOURNAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; BENZIMIDAZOLES; BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG STABILITY; MODELS, MOLECULAR; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 84871643896     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9842-z     Document Type: Article

References (35)

1. Gerloff J, Mignot A, Barth H, Heintze K. Pharmacokinetics and absolute bioavailability of lansoprazole. Eur J Clin Pharmacol. 1996;50:293-7.
2. Lew EA. Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy. Aliment Pharmacol Ther. 1999;13 Suppl 5:11-6.
3. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000;14:963-78.
4. Sohn DR, Kwon JT, Kim HK, Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin Pharmacol Ther. 1997;61:574-82.
5. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996;277:805-16.
6. Ito Y, Arai H, Uchino K, Iwasaki K, Shibata N, Takada K. Effect of adsorbents on the absorption of lansoprazole with surfactant. Int J Pharm. 2005;289:69-77.
7. DellaGreca M, Iesce MR, Previtera L, Rubino M, Temussi F, Brigante M. Degradation of lansoprazole and omeprazole in the aquatic environment. Chemosphere. 2006;63:1087-93.
8. Zhang XW, Sun NY, Wu BJ, Lu Y, Guan TZ, Wu W. Physical characterization of lansoprazole/PVP solid dispersion prepared by fluid-bed coating technique. Powder Technol. 2008;182:480-5.
9. Stroyer A, McGinity JW, Leopold CS. Solid state interactions between the proton pump inhibitor omeprazole and various enteric coating polymers. J Pharm Sci. 2006;95:1342-53.
10. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov. 2004;3:1023-35.
11. Del Valle EMM. Cyclodextrins and their uses: a review. Process Biochem. 2004;39:1033-46.
12. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85:1017-25.
13. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev. 2007;59:645-66.
14. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007;329:1-11.
15. Ventura CA, Giannone I, Paolino D, Pistara V, Corsaro A, Puglisi G. Preparation of celecoxib-dimethyl-β-cyclodextrin inclusion complex: characterization and in vitro permeation study. Eur J Med Chem. 2005;40:624-31.
16. Kang J, Kumar V, Yang D, Chowdhury PR, Hohl RJ. Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent. Eur J Pharm Sci. 2002;15:163-70.
17. Figueiras A, Sarraguca JM, Carvalho RA, Pais AA, Veiga FJ. Interaction of omeprazole with a methylated derivative of β-cyclodextrin: phase solubility, NMR spectroscopy and molecular simulation. Pharm Res. 2007;24:377-89.
18. Lu Y, Zhang XW, Lai J, Yin ZN, Wu W. Physical characterization of meloxicam-β-cyclodextrin inclusion complex pellets prepared by a fluid-bed coating method. Particuology. 2009;7:1-8.
19. Zhang XW, Wu DN, Lai J, Lu Y, Yin ZN, Wu W. Piroxicam/2-hydroxypropyl- β-cyclodextrin inclusion complex prepared by a new fluid-bed coating technique. J Pharm Sci. 2009;98:665-75.
20. Sun NY, Wei XL, Wu BJ, Chen J, Lu Y, Wu W. Enhanced dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique. Powder Technol. 2008;182:72-80.
21. Manunza B, Deiana S, Pintore M, Gessa C. Structure and internal motion of solvated β-cyclodextrine: a molecular dynamics study. J Mol Struct. 1997;419:133-7.
22. Starikov EB, Brasicke K, Knapp EW, Saenger W. Negative solubility coefficient of methylated cyclodextrins in water: a theoretical study. Chem Phys Lett. 2001;336:504-10.
23. Lawtrakul L, Viernstein H, Wolschann P. Molecular dynamics simulations of β-cyclodextrin in aqueous solution. Int J Pharm. 2003;256:33-41.
24. Jursic BS, Zdravkovski Z, French AD. Molecular modeling methodology of β-cyclodextrin inclusion complexes. J Mol Struct. 1996;366:113-7.
25. Alvira E, Mayoral JA, Garcia JI. Molecular modelling study of β-cyclodextrin inclusion complexes. Chem Phys Lett. 1997;271:178-84.
26. Faucci MT, Melani F, Mura P. Computer-aided molecular modeling techniques for predicting the stability of drug-cyclodextrin inclusion complexes in aqueous solutions. Chem Phys Lett. 2002;358:383-90.
27. Chen W, Chang CE, Gilson MK. Calculation of cyclodextrin binding affinities: energy, entropy, and implications for drug design. Biophys J. 2004;87:3035-49.
28. Lu Y, Tang N, Qi JP, Wu W. Phase solubility behavior of hydrophilic polymer/cyclodextrin/lansoprazole ternary system studied at high polymer concentration and by response surface methodology. Pharm Dev Technol. 2012;17:236-41.
29. Mura P, Bettinetti G, Melani F, Manderioli A. Interaction between naproxen and chemically modified β-cyclodextrins in the liquid and solid state. Eur J Pharm Sci. 1995;3:347-55.
30. Madrid JM, Villafruela M, Serrano R, Mendicuti F. Experimental thermodynamics and molecular mechanics calculations of inclusion complexes of 9-methyl anthracenoate and 1-methyl pyrenoate with β-cyclodextrin. J Phys Chem B. 1999;103:4847-53.
31. Ghorab MM, Abdel-Salam HM, El-Sayad MA, Mekhel MM. Tablet formulation containing meloxicam and β-cyclodextrin: mechanical characterization and bioavailability evaluation. AAPS PharmSciTech. 2004;5:e59.
32. Montassier P, Duchene D, Poelman MC. Inclusion complexes of tretinoin with cyclodextrins. Int J Pharm. 1997;153:199-209.
33. Das S, Malik S, Jain B, Saini S. Synthesis and physicochemical studies of copper complex of lansoprazole. Orient J Chem. 2009;25:1129-31.
34. He W, Yang M, Fan JH, Feng CX, Zhang SJ, Wang JX, et al. Influences of sodium carbonate on physicochemical properties of lansoprazole in designed multiple coating pellets. AAPS PharmSciTech. 2010;11:1287-93.
35. Riel MA, Kyle DE, Bhattacharjee AK, Milhous WK. Efficacy of proton pump inhibitor drugs against Plasmodium falciparum in vitro and their probable pharmacophores. Antimicrob Agents Chemother. 2002;46:2627-32.